Celsion (NASDAQ: CLSN) and Synergy Pharmaceuticals (NASDAQ:SGYP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and valuation.
This table compares Celsion and Synergy Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
6.5% of Celsion shares are owned by institutional investors. Comparatively, 44.3% of Synergy Pharmaceuticals shares are owned by institutional investors. 2.4% of Celsion shares are owned by company insiders. Comparatively, 4.8% of Synergy Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
Celsion has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Comparatively, Synergy Pharmaceuticals has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.
This is a breakdown of current recommendations and price targets for Celsion and Synergy Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Celsion presently has a consensus price target of $8.00, suggesting a potential upside of 144.65%. Synergy Pharmaceuticals has a consensus price target of $8.81, suggesting a potential upside of 366.27%. Given Synergy Pharmaceuticals’ higher possible upside, analysts plainly believe Synergy Pharmaceuticals is more favorable than Celsion.
Earnings & Valuation
This table compares Celsion and Synergy Pharmaceuticals’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Synergy Pharmaceuticals||$16.82 million||27.73||-$224.33 million||($1.02)||-1.85|
Celsion has higher earnings, but lower revenue than Synergy Pharmaceuticals. Synergy Pharmaceuticals is trading at a lower price-to-earnings ratio than Celsion, indicating that it is currently the more affordable of the two stocks.
Synergy Pharmaceuticals beats Celsion on 7 of the 13 factors compared between the two stocks.
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
About Synergy Pharmaceuticals
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.